Cipla (NSE:CIPLA, BOM:500087) received seven observations in Form 483 from the U.S. Food and Drug Administration after a follow-up current good manufacturing practices inspection of its manufacturing facility in Pithampur, India.
The regulator inspected the Pithampur facility from Aug. 17 to Aug. 25, the pharmaceutical company said in a Tuesday filing with the Indian bourses.
Cipla said it will work closely with the U.S. FDA to address the observations within the stipulated timeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.